Chronic pain

Calian Wins Contract to Support Clinical Trial for ZYUS Life Sciences’ Lead Drug Product Candidate

Retrieved on: 
Tuesday, February 20, 2024

Calian's full-service Contract Research Organization (CRO) will apply its extensive clinical trial management experience to support a Phase 2 Clinical Trial for Trichomylin softgel capsules.

Key Points: 
  • Calian's full-service Contract Research Organization (CRO) will apply its extensive clinical trial management experience to support a Phase 2 Clinical Trial for Trichomylin softgel capsules.
  • “Calian will apply our industry-leading expertise to support this Phase 2 Clinical Trial and further ZYUS’ pursuit of transformational impact on patients’ lives,” says Derek Clark, President, Calian Health.
  • Calian will provide full-service, end-to-end expertise to support this trial, including medical writing, regulatory affairs, clinical operations, site monitoring, data management, medical monitoring and quality assurance.
  • By collaborating with an industry leading contract research organization with extensive experience in clinical trial management, we can leverage invaluable knowledge and expertise."

Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain¹

Retrieved on: 
Tuesday, February 20, 2024

PALO ALTO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.

Key Points: 
  • PALO ALTO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced publication in Anesthesiology Journal of results from an investigator-initiated research study using ZTlido® for the treatment of chronic neck pain.
  • The primary outcome measure was mean reduction in average neck pain coupled with the Patient Global Impression of Change.
  • Neck pain, or cervicalgia, is one of the most common pain presentations in U.S. and the 4th leading cause of disability.
  • According to a 2020 JAMA publication (Journal of the American Medical Association), the U.S. low back and neck pain market is estimated at $134.5B.4

AIS Healthcare Recognizes Brain Injury Awareness Month

Retrieved on: 
Thursday, March 7, 2024

AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, is proud to recognize March as Brain Injury Awareness Month.

Key Points: 
  • AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, is proud to recognize March as Brain Injury Awareness Month.
  • This month reminds us of the importance of improving the quality of life for people impacted by brain injury through elevating awareness and advocacy and delivering the highest-quality healthcare.
  • “This month and every month, we seek to empower individuals living with a brain injury by delivering the best possible in-home healthcare services and pain management solutions.
  • To find more ways to support the brain injury community, contact your local brain injury association by visiting here .

Nalu Medical, Inc. Closes $85 Million Series E Round

Retrieved on: 
Tuesday, March 5, 2024

Nalu Medical, Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-pharmacologic solutions for chronic neuropathic pain, announced today the closing of an incremental $20M in equity financing from new investor B Capital, bringing the total Series E round of equity investment to $85M.

Key Points: 
  • Nalu Medical, Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-pharmacologic solutions for chronic neuropathic pain, announced today the closing of an incremental $20M in equity financing from new investor B Capital, bringing the total Series E round of equity investment to $85M.
  • Series E was led by Novo Holdings (Novo) with $65M of the total closing in late-December 2023.
  • Also participating in the round were all existing significant investors: Gilde Healthcare, MVM Partners, Endeavour Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida, and Aperture Venture Partners.
  • “The Nalu Team is committed to addressing the unmet needs of patients suffering from chronic intractable neuropathic pain.

Akston Biosciences' AKS-452 Vaccine Study Published in Nature, Showcasing Ambifect® Platform's Versatility

Retrieved on: 
Monday, February 26, 2024

This Netherlands study showed the ability of a 90 ug subcutaneous dose to safely boost the immune response of individuals previously primed with a registered mRNA- or adenovirus-based SARS-CoV-2 vaccine.

Key Points: 
  • This Netherlands study showed the ability of a 90 ug subcutaneous dose to safely boost the immune response of individuals previously primed with a registered mRNA- or adenovirus-based SARS-CoV-2 vaccine.
  • Fc-fusion protein vaccines derived from Akston’s platform provide a unique set of benefits, including inherent stability at ambient temperatures and low-cost, high-volume manufacture.
  • AKS-452 is a subunit vaccine consisting of an Fc fusion of the SARS-CoV-2 spike protein receptor binding domain (SP/RBD).
  • “Akston has also made significant strides in demonstrating the Ambifect® platform's potential beyond infectious disease vaccination,” said Todd Zion, Ph.D., President & CEO of Akston Biosciences.

MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA

Retrieved on: 
Friday, February 23, 2024

AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases.

Key Points: 
  • AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases.
  • Fasenra met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA).
  • Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States.
  • A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) (NATRON).

Curi Bio, Genetox, and DreamCIS Sign MOU for Strategic Collaboration on 3D Neuromuscular Junction Model for Botox Potency Assay

Retrieved on: 
Thursday, February 22, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240222795787/en/
    Curi Bio, Genetox, and DreamCIS Sign MOU for Strategic Collaboration on 3D Neuromuscular Junction Model for Botox Potency Assay (Photo: Business Wire)
    BoT is renowned for its therapeutic applications, including the treatment of chronic pain, autonomic disorders, congenital neuromuscular conditions, and cosmetic enhancements.
  • The project has supported Curi Bio’s development of a next-generation 3D human neuromuscular junction model used for disease modeling, for pharmaceutical and cosmetics potency assays, and for testing broad pathogenicity.
  • The project will deliver a functional potency assay for botox research and manufacture in a turnkey, scalable format.
  • With this MOU, Genetox shows its commitment to making Curi Bio’s NMJ-based potency assay a key part of BOTAONE’s manufacturing, quality control, and product release processes.

Inequalities in the face of cardiovascular risk: women the No. 1 victims

Retrieved on: 
Thursday, March 7, 2024

BOSTON, March 7, 2024 /PRNewswire/ -- Cardiovascular disease kills one women every 33 seconds in the USA10. Yet 80% of these deaths could be avoided11 through early diagnosis and awareness of symptoms and risk factors specific to women. To help reduce this excess mortality, Withings is committed to raising awareness via an exclusive survey, and providing the means to tackle their main cause: hypertension, which accounts for the majority of cardiovascular deaths.12

Key Points: 
  • Inequalities also affect health, particularly cardiovascular health: they lead to under-diagnosis and poorer care for women, resulting in avoidable excess mortality.
  • Yet 80% of these deaths could be avoided11 through early diagnosis and awareness of symptoms and risk factors specific to women.
  • Yet 50% of women are unaware of their cardiovascular risk.13
    45.9% of American women surveyed by Withings admit to putting their loved ones' health before their own.
  • Withings and cardiovascular monitoring in women: the need for a real-life, longitudinal approach
    Monitoring cardiovascular health and hypertension involves tracking a range of biomarkers.

The Inner Circle acknowledges Lars R. Newsome, MD as a Pinnacle Life Member

Retrieved on: 
Wednesday, March 6, 2024

DELMAR, Calif., March 6, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Lars R. Newsome, MD is acknowledged as a Pinnacle Life Member for his contributions to the fields of Anesthesiology and Interventional Pain Management.

Key Points: 
  • DELMAR, Calif., March 6, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Lars R. Newsome, MD is acknowledged as a Pinnacle Life Member for his contributions to the fields of Anesthesiology and Interventional Pain Management.
  • The doctor is board certified in anesthesiology, pain management, critical care management, and transesophageal echocardiography.
  • Dr. Newsome is affiliated with the San Diego Spine and Orthopedic Center and works with Dr. Eric S. Korsh.
  • A pain management specialist is a doctor who specializes in pain medicine, focusing on the evaluation, treatment and prevention of pain.

Allen Institute joins the Weill Neurohub

Retrieved on: 
Wednesday, March 6, 2024

SEATTLE, March 6, 2024 /PRNewswire/ -- The Allen Institute has officially become the newest member of the Weill Neurohub, a collaborative research network advancing treatments for neurological diseases. 

Key Points: 
  • SEATTLE, March 6, 2024 /PRNewswire/ -- The Allen Institute has officially become the newest member of the Weill Neurohub , a collaborative research network advancing treatments for neurological diseases.
  • Founded in 2003 by philanthropist Paul G. Allen, the Allen Institute focuses on big questions in biology through a team-based, open science approach, and currently has moonshot projects in neuroscience, cell biology, and immunology institutes.
  • "The expansion of the Weill Neurohub and our formal partnership with the Allen Institute represents a powerful joining of forces in neuroscience," said Stephen Hauser, M.D., the Robert A. Fishman Distinguished Professor of Neurology at UCSF and director of the UCSF Weill Institute for Neurosciences.
  • These collaborative sessions are intended to spark new joint projects and residencies, focusing on the scientific pillars of the Weill Neurohub.